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During studies to extend the half-life of crystalline nanoformulated antiretroviral therapy (nanoART) themixed lineage kinase-3 inhibitor URMC-099,
developed as an adjunctive neuroprotective agent was shown to facilitate antiviral responses. Long-acting ritonavir-boosted atazanavir (nanoATV/r)
nanoformulations co-administered with URMC-099 reduced viral load and the numbers of HIV-1 infected CD4+ T-cells in lymphoid tissues more than
either drug alone in infected humanizedNOD/SCID/IL2Rγc−/−mice. The drug effects were associatedwith sustainedART depots. Proteomics analyses
demonstrated that the antiretroviral responses were linked to affected phagolysosomal storage pathways leading to sequestration of nanoATV/r in Rab-
associated recycling and late endosomes; sites associated with viral maturation. URMC-099 administered with nanoATV induced a dose-dependent
reduction in HIV-1p24 and reverse transcriptase activity. This drug combination offers a unique chemical marriage for cell-based viral clearance.
From the Clinical Editor: Although successful in combating HIV-1 infection, the next improvement in antiretroviral therapy (nanoART) would
be to devise long acting therapy, such as intra-cellular depots. In this report, the authors described the use of nanoformulated antiretroviral therapy
given together with the mixed lineage kinase-3 inhibitor URMC-099, and showed that this combination not only prolonged drug half-life, but also
had better efficacy. The findings are hoped to be translated into the clinical setting in the future.
©2015TheAuthors.PublishedbyElsevier Inc.This is anopenaccess article under theCCBY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Long-acting nanoformulated antiretroviral therapy (nanoART) depots, at or adjacent to the viral life cycle, can improve both
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monocytes, macrophages and dendritic cells) endosomes1,5-7 can
limit hepatic ART metabolism and renal secretion.8-10 Metabolism
of HIV-1 protease inhibitors by hepatic cytochrome P450 3A
(CYP3A)11,12 may also be slowed by drug intracellular carriage.
However, the limitations of nanoART reside in the effectiveness of
the cells' depot storage capacity.We posit that the longer the storage
the longer the drug half-life. As preventative vaccines for HIV
have thus far proven ineffective, extending the time intervals for
ART administration could serve as effective pre-exposure prophy-
laxis measures and as surrogate vaccination measures. Moreover,
drug patient adherence to complex regimens may also be improved
as the effectiveness ofARThas been plagued by limitations in taking
the drugs at needed time intervals. Novel platforms designed to
achieve such goals represent “cutting edge” bench to bedside
research pursuits.
To such ends we now report a novel means to perpetuate the
ART depot in subcellular organelles. The discovery was made
during the evaluation of the mixed lineage kinase-3 (MLK3)
inhibitor URMC-099 as an adjunctive neuroprotective HIV/
AIDS therapy.13,14 Here we have shown potentiation of
nanoART effected antiretroviral responses. HIV-1 infected,
nanoART- and URMC-099-treated humanized NOD/SCID/
IL2Rγc−/− (NSG) mice showed reductions in viral load (VL)
and decreased numbers of infected lymphocytes in spleen and
lymph nodes with restoration of CD4+ T-cells in peripheral
blood. In HIV-1 infected human monocyte-derived macrophages
(MDM), URMC-099 increased nanoART retention in recycling
and late Rab protein-associated endosomes. URMC-099 facili-
tated nanoART actions by reducing residual HIV-1 in infected
NSG mice. Reduction of virus to undetectable levels beyond
what either drug can achieve alone was observed. Notably,
virus-infected lymphocytes were not observed in such treated
and infected animals. The establishment of an extended ART
depot in monocyte-macrophages is a significant step forward in
development of long-acting ART strategies for HIV/AIDS.
Moreover, combination of URMC-099 and nanoART can extend
ART half-life and improve treatment outcomes for those infected
while also serving to protect those at risk for infection.Methods
Ethics statement
All animal studies were approved by the Institutional Animal
Care and Use Committee of the University of Nebraska Medical
Center (UNMC). Animal studies were performed in compliance
with UNMC institutional policies and the National Institutes of
Health (NIH) guidelines for housing and care of laboratory
animals. Human tissues were obtained from the University of
Washington, supported by NIH award 5R24HD000836. These
studies were approved by the UNMC Institutional Review Board
(IRB), in accordance with Health and Human Services
Regulations, for the protection of human subjects. All fetal
liver tissues were anonymized without patient information or
identifiers when obtained. Human monocytes were isolated by
leukopheresis from HIV-1/2 and hepatitis seronegative donors
according to an approved UNMC IRB exempt protocol.Study design
The MLK3 inhibitor URMC-099 was tested for its abilities to
affect nanoART antiretroviral activities. First, URMC-099 was
administered to an HIV-1-infected humanized mouse model
treated with folic acid decorated-nanoART (FA-nanoART) and
antiretroviral drug concentrations measured in plasma and
tissues. Second, putative mechanisms of URMC-099 action
against HIV-1 infection were examined by SWATH proteomics
and Western blot. Third, HIV-1 integrated viral DNA, RNA,
HIV-1p24 protein and HIV-reverse transcriptase (RT) activities
were measured. Fourth, URMC-099-induced nanoART reten-
tion in cells and cellular compartments was determined by
endosomal immunoaffinity isolation, HPLC drug analysis,
mathematical simulation and confocal microscopy.
Preparation of nanoformulated ATV/r
Folic acid(FA)-conjugated-P407 was synthesized as previ-
ously described.15,16 FA-targeted and non-targeted nanoformu-
lations of atazanavir (ATV) and ritonavir (r, RTV) were
prepared as described in the Supplementary materials. Fluor-
escently-labeled nanoART was made with CF568-modified
P407 or CF633-modified P188.15
Viral infection and treatment of CD34+ NSG mice
NSG mice were reconstituted with human fetal hematopoietic
CD34+ stem cells as previously described.6 After 22-26 weeks,
mice were infected intraperitoneally (IP) with HIV-1ADA at 10
4
TCID50/mouse. Ten weeks after infection, mice were given
URMC-099 (10 mg/kg, IP) daily for three weeks with weekly
intramuscular (IM) injections of 100 mg/kg FA-modified
nanoATV/r (FA-nanoATV/r) (1:1). One week after the third
FA-nanoATV/r injection spleen, brain, liver and plasma were
collected for drug levels and antiviral activity determination17
Immunohistochemistry
Immunohistochemistry on spleen and lymph nodes was
performed.6 Tissues were stained for HLA-DR, CD45 and
HIV-1p24. Spleen sections were double stained with antibodies to
human CD3, CD68, Rab7 and HIV-1p24. Immunofluorescence
staining was captured using an LSM 510 confocal microscope (Carl
Zeiss Microimaging Inc., Dublin, CA) or by Nuance microscopy.6
Replicate tissues were collected from BALB/c mice 12 hours-post
IP injection with 100 mg/kg CF633-labeled nanoATV and
flash-frozen in Tissue-Tek O.C.T. Cryosections were stained with
antibodies to F4/80 (Abcam, Cambridge, MA) followed by a Alexa
Fluor 488 conjugated secondary antibody.
Monocyte-macrophage cultures
HumanMDMcultureswere established as previously described.18
SWATH-MS proteomics and data analyses
HumanMDMwere infected with HIV-1ADA for 4 hours, treated
with/without 100 μM nanoATV and 10 ng/mL URMC-099 for
16 hours. Cellswere harvested and proteins digested.19 Database for
Annotation, Visualization and Integrated Discovery (DAVID)
bioinformatic resource 6.7 was used for high-stringency functional
Figure 1. URMC-099 potentiates FA-nanoATV/r antiretroviral activities in humanized NSGmice. Humanized NSG mice infected with HIV-1ADA for 10 weeks
were administeredweekly intramuscular injections of 100 mg/kgFA-nanoATV/rwith orwithout daily IP injections of 10 mg/kgURMC-099.All nanoparticles usedwere
coated with FA to facilitate macrophage depot formation. After three weeks, antiviral activity was determined. (A) Human CD4+ T cells in peripheral blood during
infection in untreated (n = 5) and HIV-1 infected (n = 5) mice. (B) CD4+ T cells in mice treated with FA-nanoATV/r with (n = 7)/without URMC-099 (n = 5) or
URMC-099 only (n = 5) are presented before and after treatment. Preserved CD4+ T cell counts in nanoART alone and dual treatment groups were found. The studywas
repeated 2 times. (C) Plasma viral load measures are illustrated as average ± SEM. *, **, *** P b 0.05.
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Encyclopedia of Genes and Genomes (KEGG) Mapper Search &
Color Pathway tool was used to visualize the endocytosis pathway
with proteomics data overlay.21,22
NanoATV and URMC-099 treatment
MDMwere treated with 100 μMnative ATV or nanoATV with
or without 0.1-100 ng/ml of URMC-099. After 16 hours, MDM
were infectedwith HIV-1ADA at anMOI of 0.1 for 4 hours on day 0,
5 or 10 after drug loading. Cells were cultured for an additional
2 weeks in the absence or presence of URMC-099.
Western blots
Western blots on MDM were performed as described23 and
membranes were probed with Rab5, Rab7, Rab11, LAMP1 or
STAT1 antibodies.
HIV-1 measurements
MDM were treated with nanoATV and URMC-099, infected on
day 0 with HIV-1ADA and cultured for an additional 14 days. Genomic
DNA from MDM was extracted using the Puregene Core Kit.
IntegratedHIV-1DNAwas assessed byAlu-gag real time PCRusing a
modified protocol.24 The HIV standards were generated DNA H3B,
ACH-2 and 8E5 cell lines.25 In replicate wells, RNA fromMDMwas
isolated usingRNeasymini kit (Qiagen).HIV-1 gagRNAwas assessed
by real-time RT-PCR.26 Culture media were collected until 14 days
from HIV-1-infected MDM for RT activity measures as previously
described.9 HIV-1 p24 staining was performed as described.
MDM nanoATV uptake and retention and endocytic trafficking
Uptake and retention of nanoATV in MDM were studied.27
MDM cultured on LabTek CC2 chamber slides were treated with
100 μM CF-568-labeled nanoATV with or without 10 ng/mL
URMC-099 for 16 hours. FollowingHIV-1ADA infection at anMOI
of 0.1 for 4 hours, the infectedMDMwere cultured for an additional
14 days with 0 or 10 ng/ml URMC-099. MDM not infected with
HIV-1ADAwere cultured for 12, 24, 48 or 144 hours after nanoARTloading with 0 or 10 ng/ml URMC-099. All cells (infected and
non-infected) were fixed with ice-cold 4% PFA for 30 min, treated
with permeabilizing/blocking solution (0.1% Triton, 5% BSA in
PBS) then incubated with rabbit anti-human Rab7 or 11 or mouse
anti-human HIV-1p24. Alexa Fluor 488 goat anti-rabbit secondary
antibody detected Rab7 and 11 antibodies and Alexa Fluor 633 goat
anti-mouse secondary antibody was used for HIV-1p24. Slides were
covered with ProLong Gold anti-fade reagent with DAPI and
imaged on an LSM 510 confocal microscope (Carl Zeiss
Microimaging Inc.). Double or triple co-localization images were
analyzed using Zeiss LSM 510 Image browser AIM software
version 4.2 and Image J (NIH, Bethesda, MD) software with
BlobProb plug-in for percent overlap.8
Statistical analyses
The sample size was determined according to published
guidelines with a minimum of 5 animals per group (n = 5). All
experiments were replicated three times and results were blinded
until statistical analyses. No outliers from animal or cell experiments
were excluded. Data comparisons were analyzed using Prism
(GraphPadSoftware Inc, La Jolla, CA).One-wayANOVAwas used
to compare three or more samples followed by unpaired, two-tailed
Student's t test. The Student's t test was also used to compare two
samples. All significant differences were determined at P b 0.05.Results
URMC-099 potentiates nanoART activities in humanized
CD34+ NSG mice
Chronic immune activation potentiates HIV-1 infection and
CD4+ T-cell loss.28-30 Notably, immune deactivation reduces
pro-inflammatory activities and end-organ tissue injury.31-33
Recently, URMC-099, a MLK3 inhibitor with excellent
end-organ pharmacokinetic profiles became available to our
laboratory based on its effectiveness as an anti-inflammatory
neuroprotective agent.14,34 We reasoned that it could potentiate
nanoART as inflammation regulates Rab endosomal networks
and extend drug depot sites.8 Thus, we reasoned that URMC-099
Figure 2. Histopathological evaluation of spleen and lymph nodes from humanized mice. (A) Rare HIV-1p24+ cells are seen with FA-nanoATV/r. These
were eliminated by the addition of URMC-099. Representative images of human CD45+ and HIV-1p24+ staining (brown) are shown, 40× magnification. Scale
bar −100 μm. (B) Lymph nodes showed rare HIV-1p24+ cells in FA-nanoATV/r treated mice, which were eliminated in with URMC-099 co-treatment.
(C)Number of HIV-1p24+ cells/1000 human CD45+ cells in spleen and (D) total number of HIV-1p24+ cells in the lymph nodes are shown from five to seven
animals/group (average ± SEM). *, **, *** P b 0.05. (E) Immunofluorescence double staining for human CD3+ (red) and HIV-1p24+ (green) cells in spleen
demonstrated that HIV-1p24 infected cells are T lymphocytes. URMC-099 co-treatment with FA-nanoATV/r reduces residual lymphocyte infection in spleen.
White arrows point to T lymphocytes that are HIV-1p24+. 100× magnification. Scale bar equals 50 μm.
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human CD34+ hematopoietic-reconstituted NSG mice were
infected with HIV-1ADA at a tissue culture infective dose of 0.1
infectious virions/ml for nine weeks. Infected mice were divided
into untreated controls, URMC-099 treated, FA-nanoATV/r
treated or both. To facilitate particle entry into cells, FA was
used as the targeting ligand for nanoATV/r.15,16 FA-nanoATV/rwas administered once a week with daily URMC-099 for three
weeks. FACS tests of peripheral blood over 13-weeks demon-
strated significant gradual depletion of CD4+ T-cells in HIV-1
infected mice when compared to uninfected controls (Figure 1, A).
InHIV-1 infectedmice, CD4+ T-lymphocyteswere restored in the
FA-nanoATV/r and URMC-099 co-administered group when
compared to URMC-099 only treated mice (Figure 1, B). Before
Table 1
Endolysosomal proteins in HIV-1 or nanoATV + 099 treated MDM.
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mice was 105 copies/ml. Mice treated with FA-nanoATV/r had a
mean plasma VL of 1.6 × 103 copies/ml. Mice treated with
URMC-099 and FA-nanoATV/r had mean VL of 284 copies/ml, a
5.6-fold reduction over FA-nanoATV/r treatment alone (P b 0.01,
Figure 1,C), Treatment with URMC-099 alone did not affect theVL
compared to infected controls (NS,P = 0.2). Immunohistochemical
staining for HIV-1p24 in spleen confirmed the VL tests (Figure 2,
A). Untreated, infected animals had 40 HIV-1p24+ cells/1000
CD45+ cells in spleen. After three weeks of FA-nanoATV/r
treatment, HIV-1p24+ cells were reduced to 4 HIV-1p24+ cells/
1000 CD45+ cells (P b 0.01; Figure 2, A and C). Treatment with
URMC-099 and FA-nanoATV/r further reduced this number to
b0.1 HIV-1p24/1000 CD45+ cells (P b 0.001; Figure 2, A and C).
Double immunofluorescence staining for human CD3 and
HIV-1p24 showed that the decreases were in numbers of infected
T-cells (Figure 2, E). Pharmacokinetic analyses showed increases in
RTV from 411 to 1053 ng/g and 1471 to 3238 ng/g in spleen and
liver (P b 0.05) co-administered with URMC-099 (Supplementary
Figure 1, A and B). ATV levels were also increased from 215 to
326 ng/g in spleen, but the differences did not reach statistical
significance (P = 0.065) (Supplementary Figure 1, C). No differ-
ences in liver ATV levels were seen (Supplementary Figure 1, D).
URMC-099 facilitates nanoATV/r antiretroviral activities in
lymph nodes
Elimination of HIV-1p24+ cells in lymph nodes, by non-targeted
nanoATV/r, was not achieved in humanized NSG mice.6 In this
study, HIV-1p24+ HLA-DR+ cells in lymph nodes were reduced in
URMC-099 and FA-nanoATV/r treated mice. Untreated, infected
animals had 50.3HIV-1p24 cells/1000CD45+ cells in lymph nodes.Three weeks of FA-nanoATV/r treatment significantly reduced the
number ofHIV-1p24+cells to 10.8HIV-1p24 cells/1000HLA-DR+
cells (P b 0.005; Figure 2, B andD), but treatment with URMC-099
and FA-nanoATV/r further reduced this number to b2.3 HIV-1p24/
1000 HLA-DR+ cells (P b 0.001; Figure 2, B and D).
Proteomic analyses of virus-infected MDM
We theorized that the locus of URMC-099's interactions with
nanoATV could be the site of virion assembly based on ATV's
action. Thus, we focused our investigation on the effects of HIV-1
infection on the host cell proteome,37-41 particularly in cellular
organelles where the virus is assembled in macrophages.10,42 As
nanoATV/r accumulates in macrophages the gradual elimination of
the viral T cell reservoir is linked to drug release from its intracellular
depots. To assess the effects of nanoATV/r and URMC-099
treatments on viral replication in macrophages, proteomic tests of
whole cell lysates were performed using Sequential Windowed data
independent Acquisition of the Total High-resolution Mass Spectra
(SWATH-MS). Quantitative profiling of HIV-1 infected human
MDM demonstrated 181 up-regulated and 162 down-regulated
protein species (P b 0.05) in four replicate samples evaluated by the
paired-samples Z-test as compared to uninfected cells (Supplemen-
tary Figure 3, A and B). DAVID and KEGG bioinformatics tools
enabled functional enrichment and pathway analyses on a dataset of
438 proteins. The effect of HIV-1 infection, URMC-099 and
nanoATV is summarized in Table 1 and Figure 3, A and B. Few
numbers of proteins were altered as a consequence of URMC-099 or
nanoATV treatment in uninfected MDM. Rab5 and Rab7,
specifically, were upregulated by viral infection. This result was in
agreement with our prior findings.8,43-45 Proteins deregulated by
URMC-099 and nanoATV included Rab5, TfR, vATPase and
FcγR. Opposing regulation of phagolysomal and endosomal
proteins between HIV-1 infection and those virus-infected treated
with nanoATV with and without URMC-099 were found. To
determine if URMC-099 could alter the expression of Rab proteins
beyond what was seen by nanoATV, we examined the effects of
URMC-099 and nanoATV in HIV-1-infected or uninfected MDM.
Quantitative Western blot analyses of cell lysates showed increases
in Rab5, Rab7 and LAMP1 expressions in infected macrophages
treated with increasing concentrations of URMC-099 alone
compared with uninfected macrophages (Figure 3, C and D).
Importantly, co-treatment of uninfected and virus-infected MDM
with nanoATV and URMC-099 led to reductions in Rab5,
Rab7, STAT1 and LAMP1 expressions. These reductions were
more significant in HIV-1 infected cells for Rab7, STAT1 and
LAMP1. In the combined treatment groups, with the increasing
URMC-099 concentrations, the greatest decreases were in Rab7,
STAT1 and LAMP1.
Localization and regulation of Rab proteins in macrophages
containing nanoATV/r
To confirm these proteomic results for nanoART-macrophage
interactions, we determined the cellular distribution and subcellular
localization of nanoATV/r in vivo by injecting CF633-labeled
nanoATV/r into mice. Splenic and hepatic tissues were recovered
after animal sacrifice then stained with F4/80 antibodies to identify
macrophages. CF633 dye co-localized in macrophages (Figure 4,A)
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Figure 4. Nanoparticle uptake and characterization of Rab7 expression in human macrophages with HIV-1 infection. (A) Liver showed the presence of
CF633-labeled nanoATV (red) in mouse macrophages (F4/80-green), demonstrating clear uptake and co-localization of nanoATV in tissue resident
macrophages. Results were confirmed using 5 mice. (B) Immunofluorescence double staining of human macrophages (CD68-green) and human Rab7 (red) in
spleens of humanized mice showed an increase in the expression of co-localized Rab7 in HIV-1 infected or FA-nanoATV/r (n = 5) treated groups compared to
uninfected controls, infected mice treated with URMC-099 alone (n = 5) or double treatment (n = 7) and (C) significant increase in expression in HIV-1
infected group as compared to controls. *, **, *** P b 0.05. Scale bar equals 100 μm (Figure 4, A), 50 μm (Figure 4, B).
115G. Zhang et al / Nanomedicine: Nanotechnology, Biology, and Medicine 12 (2016) 109–122but not CD3 positive T cells in the reticuloendothelial system. In
HIV-1 infected humanized NSG mice, Rab7 expression was
increased when compared to uninfected controls (P = 0.0003;
Figure 4, B and C). A decrease of Rab7 expression, by 50%, was
observed within human macrophages in infected NSG mice treated
with URMC-099 or with nanoATV/r and URMC-099 compared to
mice treated with nanoART/r alone (P b 0.01 and 0.001,
respectively, Figure 4,B). Immunofluorescence quantitation showed
that Rab7 levels were similar in murine macrophages likely as a
result of macrophage viral infection in human cells (Supplementary
Figure 2, A and B).Figure 3. Schematic representation of the MDM phagosome network. MDM p
with URMC-099 and nanoATV treated cells. Proteins identified were compare
analyzed through the bioinformatics tools DAVID and KEGG pathway. Statistical
display up- and down-regulation, respectively. Proteins in green belong to the
deregulates phagosomal protein expressions in human MDM. The proteomics da
treated with 100 μM nanoATV for 16 hours with 0, 1, 10 or 100 ng/mL URMC-0
treatment. Cell lysates were collected on day 7 following infection. Expression
URMC-099/nanoATV treated MDM. Results are from a representative experimeURMC-099 potentiates nanoATV antiretroviral activities
Human MDM endosomes harbor both progeny virus and ART
nanoparticles.8 To assess how these drugs could influence viral
replication we treatedMDMwith nanoATV and/or URMC-099 prior
to viral exposure.After 14 days ofHIV-1ADA infection administered at
a multiplicity of infection (MOI) of 0.1, integrated HIV-1 DNA was
measured by Alu-long terminal repeat (LTR)-based real-time nested
PCR. URMC-099 had no effect on HIV-1 DNA in infected MDM.
Administration of nanoATV reduced HIV-1 integrated DNA (74
copies per 1000 cellswith nanoATVcompared to 11,471 copies/1000hagosome network identified in (A) HIV-1-infected and (B) HIV-1-infected
d against uninfected MDM cultures (P b 0.05). The acquired profiles were
significance was determined using a P-value b0.05. Proteins in red and blue,
phagosome network and not deregulated by ATV treatment. URMC-099
ta were based on experiments conducted from 4 donor MDMs. MDM were
99. HIV-1ADA infection was performed at (C) day 0 or (D) day 5 after drug
of Rab5, Rab7, STAT1, and LAMP1 were determined by Western blot in
nt. Western blots were performed in duplicates from 2 donor MDMs.
Figure 5. URMC-099 potentiates nanoATV antiretroviral activities inHIV-1 infectedMDM. URMC-099 and native ATV or nanoATV treated humanMDMwere
infectedwith HIV-1ADA and cultured for 14 days. (A)HIV-1 LTRDNAwasmeasured byAlu-gag PCR amplification (n = 4). (B) HIV-1 RNAwasmeasured byHIV-1
gag amplification (n = 4); * P b 0.05 compared to ATV treatment without URMC-099. (C) Immunocytochemical staining of HIV-1p24 expression (red). Nuclei are
stained with DAPI (blue). Immunofluorescence was quantified and is expressed as mean ± SEM. 100× Magnification. Scale bar −100 μm.
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cells was observed when URMC-099 and nanoATV were
co-administered (Figure 5, A). Reductions in RNA levels to 19
copies of HIV-1p24 gag RNA perMDMwere seen, 3-fold less than
with nanoATV alone (P b 0.05; Figure 5, B). URMC-099 also
significantly boosted antiretroviral effects of native ATV, although
to a markedly lesser extent. HIV-1p24 viral RNA was reduced to
1885 copies/cell following native ATV treatment and reduced in a
dose-dependent manner to 1250, 725 and 663 copies after
co-treatment with 0.1, 1 and 10 ng/ml URMC-099. Treatment
with URMC-099 alone did not affect HIV-1 integrated DNA and
viral RNA levels. Immunofluorescence staining of HIV-1p24
antigen in MDM showed parallel reductions after URMC-099 and
nanoATV treatments (Figure 5, C). NanoATV treatment alone
resulted in a decrease in HIV-1p24 expression of 90.8, 94.2 and
95.7%with 1, 10 and 100 μMnanoATV, respectively. Co-treatment
with URMC-099 (0.1, 1, 10 and 100 ng/ml) enhanced nanoATVHIV-1p24 suppression by 63.8, 81.7, 87.8 and 91.3%, respectively
(P b 0.05) (Figure 5, C). These results signaled the abilities of
nanoATV and URMC-099 to work in tandem to reduce viral
production but the pathway for such effects remain unclear.
To cross validate the HIV-1p24 assays and to substantiate the
antiretroviral efficacy of nanoATV and URMC-099 we next
determined levels of HIV-1 RT activity in cell culture supernatants.
HumanMDMwere treated with increasing concentrations of native
or nanoATV (0.1, 1, 10 and 100 μM)with or without 0.1 or 1 ng/ml
URMC-099. The cells were then infectedwithHIV-1ADA at anMOI
of 0.1 for 4 hours at day 0, 5 or 10 (Figure 6, A and B,
Supplementary Figure 4). RT activity was measured over 14 days
following viral infection. The rationale for waiting up to 10 days to
infect the MDM rested in the idea that URMC-099 would affect the
ATV depot and as consequence extend the drug half-life. In cells
infected on day 0, nanoATV at 0.1 μM suppressed RT activity by
approximately 10-fold while concentrations of 1-100 μM
Figure 6. URMC-099 prolongs antiretroviral activities of nanoATV in HIV-1-infected human MDM. MDM were treated with URMC-099 (0.1 or 1 ng/ml) and
nativeATVor nanoATV (100 μM) for 8 hours, and infectedwithHIV-1ADAat day0or day 5 after drug treatment.HIV-1RTactivitywasmeasured in culture supernatants
14 days after infection. RT activity inMDM treatedwith (A) nanoATVandURMC-099 or (B) nativeATV andURMC-099 are shown.Gray line = limit of detection for
assay. Data are expressed as average ± SEM (n = 4). (C) Endosomal compartments isolated from URMC-099 (10 ng/ml), native ATV or nanoATV (100 μM) treated
MDM 14 days after HIV-1 infection were evaluated for RT activity. (D) HIV-1 RT activity was determined in Rab (R) -5, -7 and -11 positive compartments. Average
activities of n = 5 replicates are shown.
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with URMC-099 (0.1 or 1 ng/ml) reduced RT activity at all
nanoATV concentrations. When the time of HIV-1 infection was
delayed to days 5 or 10 after drug treatments, co-administration of
URMC-099 at either concentration augmented 10 or 100 μM
nanoATV-induced inhibition of RT activity by an order of
magnitude (Figure 6, A, Supplementary Figure 4, C). Furthermore,
URMC-099 (1 ng/ml) and nanoATV (10 or 100 μM) inhibited RT
activity to its limit of assay detection. Treatment with native ATV
and URMC-099 did not affect RT activity levels (Figure 6, B,
Supplementary Figure 4, B).
URMC-099 affects nanoATV antiretroviral activities in
endosomal compartments
To determine the effect of URMC-099 on subcellular trafficking
of nanoATVand virus assembly, we posited that decreasedRab7 and
Rab11 expressions might also reflect a decreased number of progenyvirions in endosomal compartments. Thus, wemeasured RT activity
in the early, late and recycling endosomes. We isolated Rab
compartments fromHIV-1 infected cells treated with nanoATV and
URMC-099, using specific Rab antibody-coated magnetic beads
and measured HIV-1 RT activity in each of these compartments
(Figure 6, C). At 14 days after viral infection, 100 μM nanoATV
alone significantly reducedRT activity in all Rab-labeled endosomal
compartments, by 86, 92 and 89% for Rab5, 7- and 11-labeled
endosomes, respectively (P b 0.01, Figure 6, D). Combination of
10 ng/ml URMC-099 and 100 μMnanoATV further decreased RT
activity by 38% in Rab5-, 65% in Rab7- and 69% in Rab11-labeled
compartments compared to nanoATV alone (Figure 6, D).
URMC-099 enhances nanoATV retention in Rab7 and
Rab11 endosomes
We reasoned based on deregulation of Rab endosomal
proteins by URMC-099 and nanoATV and its relationship to
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antiretroviral drug at or adjacent to sites of the viral replication cycle.
To this end the role of URMC-099 in potentiation of nanoATV
antiviral activity was measured by assessment of nanoATV uptake
and retention in Rab-labeled endosomes. MDM were treated with
100 μM nanoATV and 10 ng/ml URMC-099; and endosomal
compartments were immunoisolated. URMC-099 had no effect on
nanoATVuptake into eitherwhole cells or subcellular compartments
(Figure 7, A, Supplementary Figure 5). However, 10 ng/ml
URMC-099 significantly enhanced cellular retention of nanoATV
from 35.9 to 52.3 μg ATV/106 cells at 3 days (P b 0.05;
Supplementary Figure 5), and increased nanoATV retention in
Rab5, Rab7, and Rab11 endosomal compartments compared to
MDM treated with nanoATV alone (P b 0.05; Figure 7, B). A
simulated flow of nanoparticles and mathematical analyses is
presented in Figure 7, C and Supplementary Figure 6, which
demonstrates the enhanced retention of nanoATV in Rab7 and
Rab11 compartments.
URMC-099 enhances nanoATV at sites of virion assembly
We next evaluated the ability of URMC-099 to enhance
nanoATV accumulation in Rab-labeled endosomal compartments.
The co-localization of fluorescently labeled nanoATV with
endosomes labeled by fluorescently tagged Rab antibodies was
determined in human MDM. URMC-099 increased the level of
nanoATV in Rab7 and Rab11 endosomes (Figure 7, D-G). Ten
nanograms per milliliter of URMC-099 increased nanoATV levels
in both Rab7 and Rab11 endosomes (Figure 7, D-G). ATV
concentrations persisted to 6 days. AsRab7 andRab11 endosomes
contain HIV-1 virions, we determined whether HIV-1p24 and
nanoATV were co-localized in these organelles (Supplementary
Figure 7, A and B). Confocal microscopy demonstrated that Rab7-
or 11-labeled endosomes (expressed as a coefficient of overlap in a
Z-stack of XY images) contained HIV-1p24 and nanoATV.When
treated with nanoATV alone, these coefficients of overlap were
0.41 and 0.48, respectively (Supplementary Figure 7, C and D).
Importantly, they were significantly increased to 0.55 and 0.66
(P b 0.05), when URMC-099 was co-administered with
nanoATV. To explore the relationship by which URMC-099
could affect such viral and endosomal drug trafficking we are
currently studying how Rab proteins are regulated in HIV-1
infected and nanoATV-treated macrophages.Discussion
URMC-099 boosts the antiretroviral activities of long-acting
nanoART. As progeny virion trafficking occurs largely within these
endosomal compartments, the nanoparticle–cell interactions ofFigure 7. URMC-099 facilitates retention of nanoATV in endosomal compar
10 ng/ml URMC-099 for 16 hours then maintained for an additional 15 days. Subc
antibody coated magnetic beads. (A) MDM nanoATV drug levels into individua
nanoATV over 15 days (360 hours) in endosomes after the 16-hour loading (aver
(C) Mathematical simulation of nanoATV retention in individual endosomal com
accumulation in Rab7 endosomal compartments. (E) URMC-099 increases n
Arrowheads point to dual labeled Rab compartments and nanoparticles. CF568
compartment shows as green. DAPI (blue) indicates cell nuclei, 1260× magnificat
(average ± SEM, n = 30, unpaired 2-tailed t test); * P b 0.05 compared to respecURMC-099 led to improved antiretroviral outcomes. The findings
buttress an URMC-099-ART marriage by a surprising ability of the
drugs to increase ART retention in virus-containing subcellular
compartments. This occurred in lymph node viral reservoir compart-
ments. The extension of the half-life of ART by URMC-099 provides
novel therapeutic opportunities for HIV-1 prevention and buttresses
what is now known for nanoART (Figure 8).
The convergence of the drug–drug actions revolves around
the therapeutic potential of long-acting nanoART. This is based
on the nanoparticles' ability to maintain effective drug
concentration in cellular and tissue depots and thus improve
drug pharmacokinetics. Indeed, poorly water-soluble crystalline
nanoformulations affect drug stability. Drug particles can also
remain within sites of injection in subcutaneous tissue or
muscle.6,15 Utilization of peripheral blood mononuclear cells as
drug carriers thus presents a novel treatment scheme.46,47 Cell
based drug delivery can now be harnessed to improve disease
outcomes while overcoming physiologic barriers such as
improved drug entry into viral reservoirs.48,49 Such therapeutic
enhancements may be further improved by modification of the
coating surface of nanoparticles.50 Targeting ligands, such as
FA, mannose, hyaluronic acid or HIV-1gp120, are being
developed to facilitate uptake and retention of nanoART.15,51
The endocytic pathway constitutes the uptake to cells, the
out-going route being the biosynthetic pathway.52 In addition the
endosome is responsible for mediating the uptake of nutrients, the
propagation of signaling and regulation of receptors.53 The
endosomal system also plays an indispensable role in retroviral
assembly. The envelope glycoprotein, known as Env, is one of the
vital components of a retrovirus,which traffics through the endocytic
pathway.54 Env expressed in infected macrophages is located in
intracellular membranes of the endocytic pathway or in trans-Golgi
network.55 HIV-1 assembly in macrophages may occur, in part,
from the limitingmembrane of a late endosomal compartment linked
to in multi-vesicular bodies.25 Viruses might be able to hide in these
late endosomes, sequestered away from the immune system.
What's more, late endosomes and lysosomes are part of the major
histocompatibility complex class II compartment, a lysosome-
related organelle with properties similar to secretory lysosomes.56
Viral particle accumulation can occur inside late
endosomes.57 During native drug administration, such intracel-
lular virus-containing compartments are resistant to antiretroviral
drug penetration and retention since less endolysosomal proteins
are related to native drug treatment.58 The modification of the
endosomal trafficking route by drug-loaded nanoparticles could
significantly improve antiretroviral drug efficacy as our data
demonstrate that HIV-1 can hijack Rab7 and Rab11 endosomes
for virus maturation; this could be circumvented through
URMC-099. Indeed, URMC-099's dual effects on Rab proteintments. Human MDM were treated with 100 μM nanoATV with or without
ellular compartments were isolated by immunoaffinity chromatography using
l endosomal compartments over 16 hours were measured. (B) Retention of
age ± SEM, n = 5). All cell retention and uptake studies are repeated 3 times.
partments over the same time frame. (D) URMC-099 potentiates nanoATV
anoATV accumulation in Rab11 endosomal compartments. (D and E)
-labeled nanoATV shows as red, while AlexaFluor 488-labeled endosomal
ion. Percent overlap of nanoATV with (F) Rab7 and (G) -11 was quantitated
tive time point. Scale bar = 20 μm.
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ments in drug action by improving ART delivery to subcellular
compartments by several divergent means. First, URMC-099
can affect redistribution of nanoparticles in the late and recycling
endosomes. Second, URMC-099 cannot, by itself, inhibit HIV-1
replication. Third, deactivation of macrophages through sup-
pression of the MAP kinase signaling pathway can restrict
transcription of pro-inflammatory cytokine-induced immune
responses.59,60Fourth, virus-immune control of Rab protein
expression and function is operative.61 Modulation of macro-
phage activation can affect Rab protein expression and regulate
intracellular endocytosis. Fifth, progeny virions can be assem-
bled in identical or adjacent compartments affected by immune
responses. Sixth, this is the first combinatorial formulation
known to date to reach the lymph nodes of infected animals and
reduce, by more than 90%, the numbers of infectious viral
particles. Thus, nanoART and URMC-099 would perform
synergistic functions by affecting intrinsic macrophage activa-
tion. Both would result in reduction of Rab protein expression.
Perhaps more importantly, the pharmacologic and pharmacody-
namic characteristics of URMC-099 bode well for inclusion in
the next generation of nanoformulated antiretroviral therapy to
combat persistent HIV-1 infection. While targeting viral mono-
cyte-macrophage viral reservoirs is one component that supports the
abilities of this cell carriage system to reduce residual HIV-1,
nanoparticles encased in cells can affect drug transfer to CD4+ T
lymphocytes and improve antiretroviral activities.Acknowledgments
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